The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

News headlines Recursion Pharmaceuticals (RXRX) is gaining attention due to positive clinical trial results for its drug REC-4881 and a recent upgrade by JPMorgan. Cathie Wood's ARK Investment also ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Xavier Lorenzo / GettyImages If you're looking for a loan, finding the most affordable ...